Evidence map›Paper›PMID 25348256›Full record

ArticleProstate cancer and prostatic diseases2015

The association between race and treatment regret among men with recurrent prostate cancer.

B A Mahal, M-H Chen, C L Bennett, M W Kattan, O Sartor, K Stein, A V D'Amico, P L Nguyen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Prostate brachytherapy in Ghana: our initial experience.Journal of contemporary brachytherapy · 2016
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 1 country.

B A MahalHarvard Medical School, Boston, MA, USA.
M-H ChenDepartment of Statistics, University of Connecticut, Storrs, CT, USA.
C L BennettSouth Carolina College of Pharmacy, Hollings Cancer Center, Charleston, SC, USA.
M W KattanDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.
O SartorDepartment of Medicine and Urology, Tulane University, New Orleans, LA, USA.
K SteinNovartis, East Hanover, NJ, USA.
A V D'AmicoDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
P L NguyenDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brigham and Women's Hospital · USCleveland Clinic · USDana-Farber Cancer Institute · USHarvard University · USMUSC Hollings Cancer Center · USNovartis (United States) · USTulane University · USUniversity of Connecticut · US

Funding

Southern Oncology Network on Adverse Reactions (SONAR) - Focus on Tyrosine KinaseR01CA165609 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI BENNETT, CHARLES L. · 2012 to 2016
$2.2M
NCI NIH HHS R01 CA165609
6 · The paper itself

Abstract

backgroundTo examine the impact of race on treatment regret among men with recurrent prostate cancer after surgery or radiation.

methodsThe prospective Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma (COMPARE) registry was used to study a cohort of 484 men with biochemically recurrent prostate cancer after radical prostatectomy, external beam radiation or brachytherapy. Multivariable logistic regression was used to model the association between race and treatment regret and to determine whether there was an interaction between race and sexual problems after treatment with regards to treatment regret.

resultsBlack men (N=78) were significantly more likely to have treatment regret when compared with non-black men (N=406; 21.8% versus 12.6%) on univariable analysis (odds ratio (OR) 1.94; 95% confidence interval 1.05-3.56; P=0.03). On multivariable analysis, black race trended towards but was no longer significantly associated with an increase in treatment regret (adjusted OR (AOR) 1.84 (0.95-3.58); P=0.071). There was an interaction between race and sexual problems after treatment (Pinteraction=0.02) such that among those without sexual problems, black men had more treatment regret than non-black men (26.7% versus 8.4%: AOR 4.68 (1.73-12.63); P=0.002), whereas among those with sexual problems, there was no difference in treatment regret between black and non-black men (18.8% versus 17.3%: AOR 1.04 (0.44-2.46); P=0.93).

conclusionsAmong men with recurrent prostate cancer after surgery or radiation, black men were nearly twice as likely to experience treatment regret. Treating physicians should ensure that patients are fully apprised of the pros and cons of all treatment options to reduce the risk of subsequent regret.

Indexed as

EmotionsAgedAged, 80 and overBlack PeopleBrachytherapyHumansMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesProstatectomyProstatic NeoplasmsTreatment Outcome

Identifiers

PMID25348256
PMCPMC5105596
OpenAlexW2082034234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.